HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.74 USD
+0.02 (0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HOOK 4.74 +0.02(0.42%)
Will HOOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOOK
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
HOOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Other News for HOOK
HOOKIPA Pharma Announces Board of Directors Changes
Hookipa Pharma appoints O'Neill as non-executive chair of board
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024